Alan F. Denenberg

Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…

Davis Polk advised Equinix, Inc. on its SEC-registered follow-on public offering of 2,985,575 shares of common stock including 389,422 shares that the underwriters…

Davis Polk advised the joint book-running managers on the SEC-registered offering by Lam Research Corporation of $750 million aggregate principal amount of its 3.750% senior notes due 2026,…

Davis Polk advised the underwriters in connection with a $644 million public offering of GoDaddy Inc. Class A common stock. Certain existing stockholders sold 8,538,616 shares and GoDaddy…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Weyerhaeuser Company of $750 million aggregate principal amount of its 4.00% senior notes due 2029…

Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed on the…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by 8x8, Inc. of $287.5 million aggregate principal amount of its 0.50% convertible…

Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…

Davis Polk advised Equinix, Inc. in connection with its SEC-registered at-the-market offering of its shares of common stock for up to an aggregate amount of $750 million.Equinix, Inc…

Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…